Research analysts at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a note issued to investors on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
NASDAQ:EVOK opened at $5.79 on Monday. The firm has a market capitalization of $4.74 million, a price-to-earnings ratio of -0.36 and a beta of 0.36. Evoke Pharma has a 1 year low of $3.54 and a 1 year high of $17.88. The business has a 50 day simple moving average of $4.96 and a 200-day simple moving average of $5.51.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). The company had revenue of $2.55 million for the quarter. Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Articles
- Five stocks we like better than Evoke Pharma
- What is the Euro STOXX 50 Index?
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Stock Splits, Do They Really Impact Investors?
- Insider Buying Signals Upside for These 3 Stocks
- The Most Important Warren Buffett Stock for Investors: His Own
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
